Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Praxis Precision Medicines (PRAX) EBITDA: 2019-2024

Historic EBITDA for Praxis Precision Medicines (PRAX) over the last 6 years, with Dec 2024 value amounting to -$200.2 million.

  • Praxis Precision Medicines' EBITDA fell 37.87% to -$78.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$293.1 million, marking a year-over-year decrease of 78.71%. This contributed to the annual value of -$200.2 million for FY2024, which is 58.39% down from last year.
  • Latest data reveals that Praxis Precision Medicines reported EBITDA of -$200.2 million as of FY2024, which was down 58.39% from -$126.4 million recorded in FY2023.
  • Praxis Precision Medicines' EBITDA's 5-year high stood at -$62.0 million during FY2020, with a 5-year trough of -$215.0 million in FY2022.
  • Over the past 3 years, Praxis Precision Medicines' median EBITDA value was -$200.2 million (recorded in 2024), while the average stood at -$180.5 million.
  • Its EBITDA has fluctuated over the past 5 years, first crashed by 170.03% in 2021, then surged by 41.22% in 2023.
  • Over the past 5 years, Praxis Precision Medicines' EBITDA (Yearly) stood at -$62.0 million in 2020, then plummeted by 170.03% to -$167.3 million in 2021, then decreased by 28.48% to -$215.0 million in 2022, then surged by 41.22% to -$126.4 million in 2023, then slumped by 58.39% to -$200.2 million in 2024.